Immuneering Corporation (IMRX) 10-Year Financial Performance & Capital Metrics

IMRX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutImmuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.Show more

Revenue $0
EBITDA -$64M -9.7%
Net Income -$61M -14.1%
EPS (Diluted) -2.04 -8.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -92.51% -73.4%
ROIC -213.39% -89.2%
Debt/Equity 0.10 +104.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 80 (top 20%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-7.63%

EPS CAGR

10Y-

5Y-

3Y-

TTM9.64%

ROCE

10Y Avg-55.72%

5Y Avg-57.61%

3Y Avg-61.68%

Latest-91.56%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.92M	2.31M	2.08M	316.95K	0	0
Revenue Growth %	-	0.2%	-0.1%	-0.85%	-1%	-
Cost of Goods Sold+	1.22M	1.28M	1.15M	158.12K	0	0
COGS % of Revenue	0.64%	0.55%	0.55%	0.5%	-	-
Gross Profit+	696.74K	1.03M	926.89K	158.83K	0	0
Gross Margin %	0.36%	0.45%	0.45%	0.5%	-	-
Gross Profit Growth %	-	0.48%	-0.1%	-0.83%	-1%	-
Operating Expenses+	6.99M	18.11M	34.81M	51.9M	58.41M	64.07M
OpEx % of Revenue	3.64%	7.84%	16.74%	163.76%	-	-
Selling, General & Admin	2.71M	3.11M	8.27M	15.61M	16.76M	16.08M
SG&A % of Revenue	1.41%	1.35%	3.98%	49.24%	-	-
Research & Development	4.28M	15M	26.54M	36.27M	41.62M	47.96M
R&D % of Revenue	2.23%	6.49%	12.76%	114.42%	-	-
Other Operating Expenses	0	0	-2	29.58K	28.87K	29.01K
Operating Income+	-6.29M	-17.08M	-33.89M	-51.74M	-58.41M	-64.07M
Operating Margin %	-3.28%	-7.39%	-16.29%	-163.26%	-	-
Operating Income Growth %	-	-1.72%	-0.98%	-0.53%	-0.13%	-0.1%
EBITDA+	-6.27M	-17M	-33.73M	-51.47M	-58.06M	-63.69M
EBITDA Margin %	-3.27%	-7.36%	-16.22%	-162.38%	-	-
EBITDA Growth %	-	-1.71%	-0.98%	-0.53%	-0.13%	-0.1%
D&A (Non-Cash Add-back)	18.08K	79.31K	159.07K	277.25K	352.08K	385.07K
EBIT	-7.36M	-17.08M	-33.89M	-51.75M	-58.41M	-64.07M
Net Interest Income+	-293.64K	42.66K	169.9K	1.01M	3.61M	2.59M
Interest Income	57.66K	42.66K	169.9K	1.01M	3.61M	2.59M
Interest Expense	351.3K	0	0	0	0	0
Other Income/Expense	-1.42M	-41.7K	42.83K	1.23M	4.94M	3.03M
Pretax Income+	-7.71M	-17.12M	-33.84M	-50.51M	-53.47M	-61.04M
Pretax Margin %	-4.02%	-7.41%	-16.27%	-159.37%	-	-
Income Tax+	0	-84.34K	-307.49K	0	0	0
Effective Tax Rate %	1%	1%	0.99%	1%	1%	1%
Net Income+	-7.71M	-17.04M	-33.54M	-50.51M	-53.47M	-61.04M
Net Margin %	-4.02%	-7.37%	-16.12%	-159.37%	-	-
Net Income Growth %	-	-1.21%	-0.97%	-0.51%	-0.06%	-0.14%
Net Income (Continuing)	-7.71M	-17.04M	-33.54M	-50.51M	-53.47M	-61.04M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.60	-1.26	-1.27	-1.87	-1.88	-2.04
EPS Growth %	-	-1.1%	-0.01%	-0.47%	-0.01%	-0.09%
EPS (Basic)	-0.60	-1.26	-1.27	-1.87	-1.88	-2.04
Diluted Shares Outstanding	13.51M	13.51M	26.32M	26.39M	28.42M	29.98M
Basic Shares Outstanding	13.51M	13.51M	26.32M	26.39M	28.42M	29.98M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	14.06M	37.73M	152.33M	108.75M	89.08M	39.59M
Cash & Short-Term Investments	13.78M	37.09M	149.2M	105.52M	85.67M	36.14M
Cash Only	13.78M	37.09M	74.89M	72.64M	59.41M	36.14M
Short-Term Investments	0	0	74.31M	32.89M	26.26M	0
Accounts Receivable	209.94K	500.11K	246.04K	12.42K	0	0
Days Sales Outstanding	39.92	78.97	43.18	14.3	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	0	3.21M	3.42M	3.44M
Total Non-Current Assets+	35.28K	691.8K	14.37M	13.62M	13.5M	13.13M
Property, Plant & Equipment	35.28K	677.47K	6.13M	5.78M	5.4M	4.79M
Fixed Asset Turnover	54.42x	3.41x	0.34x	0.05x	-	-
Goodwill	0	0	6.7M	6.69M	6.69M	6.69M
Intangible Assets	0	0	439K	408.95K	379.68K	350.41K
Long-Term Investments	0	0	996.56K	0	0	0
Other Non-Current Assets	0	14.33K	102.13K	743.7K	1.03M	1.3M
Total Assets+	14.1M	38.42M	166.7M	122.37M	102.58M	52.71M
Asset Turnover	0.14x	0.06x	0.01x	0.00x	-	-
Asset Growth %	-	1.73%	3.34%	-0.27%	-0.16%	-0.49%
Total Current Liabilities+	505.3K	2.26M	5.63M	8.05M	7.85M	7.5M
Accounts Payable	294.95K	1.48M	1.39M	3.15M	2.11M	1.96M
Days Payables Outstanding	88.03	422.08	441.37	7.28K	-	-
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	118.72K	163.67K	2.92M	3.65M	3.89M	3.82M
Current Ratio	27.83x	16.73x	27.04x	13.50x	11.35x	5.28x
Quick Ratio	27.83x	16.73x	27.04x	13.50x	11.35x	5.28x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	20.12M	58.65M	5.09M	4.46M	4.16M	3.82M
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	544.77K	5.09M	4.46M	4.16M	3.82M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	20.12M	58.1M	0	0	0	0
Total Liabilities	20.63M	60.9M	10.72M	12.52M	12.01M	11.33M
Total Debt+	0	621.09K	5.36M	4.84M	4.46M	4.16M
Net Debt	-13.78M	-36.47M	-69.52M	-67.8M	-54.94M	-31.98M
Debt / Equity	-	-	0.03x	0.04x	0.05x	0.10x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-17.91x	-	-	-	-	-
Total Equity+	-6.53M	-22.48M	155.98M	109.85M	90.58M	41.39M
Equity Growth %	-	-2.44%	7.94%	-0.3%	-0.18%	-0.54%
Book Value per Share	-0.48	-1.66	5.93	4.16	3.19	1.38
Total Shareholders' Equity	-6.53M	-22.48M	155.98M	109.85M	90.58M	41.39M
Common Stock	4.95K	4.95K	26.32K	26.42K	29.27K	31.05K
Retained Earnings	-8.7M	-25.74M	-59.27M	-109.79M	-163.26M	-224.3M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	-49.01K	-30.12K	-778	0
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.44M	-14.62M	-30.85M	-44.1M	-48.97M	-55M
Operating CF Margin %	-2.31%	-6.33%	-14.83%	-139.14%	-	-
Operating CF Growth %	-	-2.29%	-1.11%	-0.43%	-0.11%	-0.12%
Net Income	-7.71M	-17.04M	-33.54M	-50.51M	-53.47M	-61.04M
Depreciation & Amortization	18.08K	79.31K	159.07K	796.79K	352.08K	385.07K
Stock-Based Compensation	596.63K	1.09M	1.8M	0	5.73M	6.5M
Deferred Taxes	0	0	-307.49K	0	0	0
Other Non-Cash Items	2.22M	0	130.24K	3.9M	-601.59K	75.98K
Working Capital Changes	437.13K	1.25M	900.42K	1.72M	-974.64K	-925.38K
Change in Receivables	614.11K	-290.17K	279.71K	233.62K	12.42K	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	270.5K	1.19M	-130.4K	1.76M	-1.11M	-112.14K
Cash from Investing+	-20.53K	-53.41K	-75.62M	41.83M	7.3M	26.43M
Capital Expenditures	-20.53K	-53.41K	-60.79K	-742.48K	-342.75K	-84.88K
CapEx % of Revenue	0.01%	0.02%	0.03%	2.34%	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	-75.62M	0	0	0
Cash from Financing+	17.17M	37.98M	144.26M	19K	28.44M	5.3M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	-56.24K	0	-842.76K	0	241.07K	1.07M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-4.46M	-14.67M	-30.91M	-44.84M	-49.31M	-55.08M
FCF Margin %	-2.32%	-6.35%	-14.86%	-141.48%	-	-
FCF Growth %	-	-2.29%	-1.11%	-0.45%	-0.1%	-0.12%
FCF per Share	-0.33	-1.09	-1.17	-1.70	-1.74	-1.84
FCF Conversion (FCF/Net Income)	0.58x	0.86x	0.92x	0.87x	0.92x	0.90x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-50.24%	-38%	-53.36%	-92.51%
Return on Invested Capital (ROIC)	-	-	-184.79%	-60.4%	-112.78%	-213.39%
Gross Margin	36.29%	44.61%	44.56%	50.11%	-	-
Net Margin	-401.59%	-737.17%	-1612.33%	-15937.29%	-	-
Debt / Equity	-	-	0.03x	0.04x	0.05x	0.10x
Interest Coverage	-17.91x	-	-	-	-	-
FCF Conversion	0.58x	0.86x	0.92x	0.87x	0.92x	0.90x
Revenue Growth	-	20.41%	-10.02%	-84.76%	-100%	-

Frequently Asked Questions

Growth & Financials

Immuneering Corporation (IMRX) grew revenue by 0.0% over the past year. Growth has been modest.

Immuneering Corporation (IMRX) reported a net loss of $62.5M for fiscal year 2024.

Dividend & Returns

Immuneering Corporation (IMRX) has a return on equity (ROE) of -92.5%. Negative ROE indicates the company is unprofitable.

Immuneering Corporation (IMRX) had negative free cash flow of $50.0M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener